semaglutide patent india With semaglutide's expiring, generics are set to enter from soon, setting off competition in a fast-growing segment of obesity and diabetes care. https://timesofindia.indiatimes.com/toi-plus/business-economy/why-miracle-weight-loss-drugs-are With an eye on rivals,

According to the FDA prescribing information for Wegovy, in the STEP clinical trials, cholelithiasis was reported in approximately 1.6% of semaglutide-treated patients compared to 0.7% of placebo recipients

[1] [2] In rodent studies, semaglutide caused thyroid C-cell tumors at clinically relevant exposures, and while the relevance to humans remains uncertain, the FDA-approved labeling includes a boxed warning regarding this risk

So what does this mean for your Semaglutide-fueled goals

Wegovy is FDA-approved for weight loss and management in adults with obesity or overweight who have at least one weight-related health condition (e.g., high blood pressure, diabetes), as well as adults and children ages 12 and older with obesity